GLP-1 and dual incretin medications (semaglutide, tirzepatide) produce substantial weight loss — but published clinical trial data show that ~25–45% of that weight loss can be lean mass, not fat, depending on the medication, the dose, the patient, and whether resistance training and protein intake are optimized. The scale cannot tell you what you are losing. A DEXA scan can. Every adult starting a GLP-1 should have a baseline scan and a 3-month follow-up.
Find a DEXASCAN.com clinic near you →
Why GLP-1 Users Need a Different Approach to Tracking Weight Loss
Glucagon-like peptide-1 (GLP-1) receptor agonists — semaglutide (Wegovy, Ozempic), liraglutide, and the dual GLP-1/GIP agonist tirzepatide (Zepbound, Mounjaro) — have rewritten what medical weight loss looks like. Average weight loss in pivotal trials has ranged from approximately 15% with semaglutide (STEP 1) to approximately 21% with tirzepatide (SURMOUNT-1) at therapeutic doses over roughly 68–72 weeks.
That weight loss is real, and the cardiometabolic benefits are real. But the quality of that weight loss — how much is fat versus muscle versus water versus bone — is the difference between an outcome that supports long-term health and an outcome that quietly sets up sarcopenia, osteopenia, and weight regain when treatment stops.
Here is the central problem: your bathroom scale cannot answer this question. A 30-pound weight loss could be 30 pounds of fat (excellent), or it could be 20 pounds of fat and 10 pounds of muscle (substantially worse). The scale shows the same number either way.
A whole-body DEXA scan at a DEXASCAN.com clinic shows you exactly what kind of weight you are losing — and gives you the data to course-correct before muscle loss becomes a long-term problem.
What the Published Research Actually Says About Lean Mass Loss on GLP-1s
The body of evidence on body composition changes during GLP-1 therapy has grown substantially in 2025–2026. The key findings:
Semaglutide (STEP 1 substudy and clinical data)
A 2025 review published in Reviews in Endocrine and Metabolic Disorders summarized DEXA-derived body composition outcomes across pivotal trials. For semaglutide, approximately 40–45% of total weight loss was lean mass in the STEP 1 DEXA substudy population, with the remainder being fat mass.[^1] The STEP 1 DEXA analysis specifically reported a mean lean body mass change of –5.8 kg over 68 weeks in the semaglutide 2.4 mg group.[^2]
Tirzepatide (SURMOUNT-1 and follow-on analyses)
For tirzepatide, the same review reported that approximately 25.7% of total weight loss was lean mass — a more favorable ratio than semaglutide, though the underlying mechanism remains unclear. The current hypothesis is that GLP-1/GIP dual agonism may produce more preferential fat loss than GLP-1 monotherapy.[^1] A 2025 Circulation state-of-the-art review concluded that, on the basis of MRI-derived muscle volume data, skeletal muscle changes with GLP-1 therapy appear to be largely adaptive — proportional to what would be expected with any weight loss intervention — rather than maladaptive muscle wasting.[^3]
Real-world data: SEMALEAN study (2025)
The 2025 SEMALEAN prospective study enrolled 115 patients with obesity (mean BMI 46.3 kg/m²) on semaglutide 2.4 mg and followed them for 12 months with DEXA-measured body composition. Results: mean weight loss of 13% at 12 months, with total fat mass decreasing by 18% and lean mass initially declining by ~3 kg at 7 months before stabilizing. Handgrip strength was preserved.[^4]
Real-world comparative data: 670,000-patient analysis (2026)
A 2026 medRxiv preprint analyzing 670,422 first-episode GLP-1 patients in routine clinical care found that lean body mass decline was greater with tirzepatide than with semaglutide in real-world use — the opposite of what trial-population data suggested. The authors attribute this to differences in patient populations, dose titration practices, and absence of structured exercise interventions in routine care versus clinical trial settings.[^5]
The mechanism: weight loss + age = muscle loss risk
Approximately 25% lean mass loss as a fraction of total weight loss is roughly in line with what occurs during any caloric restriction or weight loss intervention in adults. The issue is not that GLP-1s uniquely cause muscle loss — it is that they produce dramatic, rapid, and sustained weight loss in an aging population, often without the structured resistance training and high-protein intake that would mitigate lean mass loss.[^6]
The bottom line: GLP-1-driven lean mass loss is real, variable between patients, partially preventable, and completely invisible to the scale.
What Happens If You Lose Muscle With Your Fat
The clinical consequences of disproportionate lean mass loss during GLP-1 therapy are serious:
1. Reduced resting metabolic rate
Muscle is metabolically expensive tissue. Losing lean mass reduces your daily caloric expenditure — making weight maintenance harder when treatment ends or doses are reduced.
2. Accelerated sarcopenia
Sarcopenia — the age-related loss of muscle mass and function — is the single most well-established biomarker of frailty, falls, fractures, disability, and all-cause mortality in older adults. GLP-1-driven muscle loss layered on top of normal age-related sarcopenia can substantially accelerate the timeline to clinically meaningful muscle deficiency.
3. Increased fracture risk
Lower muscle mass and lower body weight together can reduce bone mineral density over time, particularly in postmenopausal women — increasing fracture risk in exactly the population most likely to benefit from GLP-1 weight loss otherwise.
4. Weight regain composition asymmetry
When patients discontinue or reduce GLP-1 therapy, regained weight is predominantly fat, not muscle — meaning the post-treatment body composition can end up worse than the pre-treatment baseline even if total weight is similar.
5. Functional decline
Reduced muscle strength affects daily function, exercise capacity, and quality of life — outcomes that can erode the substantial benefits GLP-1 medications otherwise provide.
For a deeper look at the muscle metric most clinically tied to these outcomes, see: Appendicular Lean Mass Index (ALMI): The DEXA Scan Number That Predicts How Well You'll Age.
What the Scale Cannot Tell You
Three months into GLP-1 therapy, your scale shows 22 pounds lost. Excellent — except the scale will not tell you which of the following you actually are:
| Scenario | Fat lost | Lean lost | What it looks like at 12 months |
|---|---|---|---|
| Optimal outcome | 18 lb (82%) | 4 lb (18%) | Reduced fat mass, preserved muscle, strong metabolic profile |
| Average outcome | 15 lb (68%) | 7 lb (32%) | Solid fat loss, modest muscle loss — typical without structured intervention |
| Suboptimal outcome | 11 lb (50%) | 11 lb (50%) | Muscle loss disproportionate to fat loss — accelerated sarcopenia trajectory |
| Concerning outcome | 8 lb (36%) | 14 lb (64%) | Predominantly muscle loss — clinical intervention warranted |
Every one of those scenarios produces the same number on your scale. Without body composition measurement, you have no idea which one you are.
A DEXA scan resolves the ambiguity in 10 minutes.
The Recommended DEXA Scan Protocol for GLP-1 Users
Based on the published research and clinical practice patterns at body composition-focused clinics, the protocol most likely to detect and prevent suboptimal body composition outcomes is:
Scan 1: Baseline (before starting GLP-1 or within 2 weeks of initiation)
Establishes the starting reference for:
- Total body weight and BMI (for context)
- Total body fat % and Fat Mass Index (FMI) — the fat you are targeting
- Visceral Adipose Tissue (VAT) — the metabolically dangerous fat
- Total lean mass and Appendicular Lean Mass Index (ALMI) — the muscle you are protecting
- Bone Mineral Density (BMD) — the bone you are protecting
- Regional body composition — left/right and upper/lower distribution
Without this baseline, all subsequent measurements lose context. You cannot tell whether your body composition is improving, worsening, or stable.
Scan 2: 3-month follow-up
This is the highest-yield scan in the entire protocol. Three months in, you are typically at 5–10% total body weight loss — enough that body composition changes are clearly measurable, but early enough that course corrections can still meaningfully shift the 12-month outcome.
Key questions answered by the 3-month scan:
- Is fat loss accounting for the majority of weight loss? (Target: ≥70% of weight loss as fat)
- Has ALMI dropped significantly? (Target: minimal change)
- Has VAT decreased? (Target: substantial reduction — this is what most of the metabolic benefit comes from)
- Has BMD changed? (Target: stable)
Scan 3: 6-month follow-up
Confirms whether early trends have continued or whether interventions implemented after Scan 2 (added resistance training, increased protein, etc.) have worked.
Scan 4: 9-month follow-up
Documents the full first-year outcome and informs whether dose adjustments, maintenance protocols, or discontinuation strategies make sense.
Beyond year 1
For patients continuing GLP-1 therapy long-term, every 3-6 months is appropriate. For patients discontinuing or tapering, scans every 3–6 months during the transition help detect compositional shifts (particularly the asymmetric fat-vs-muscle regain pattern) early.
Schedule your baseline GLP-1 DEXA scan at a DEXASCAN.com clinic →
Why You Should Track Between DEXA Scans With an At-Home Body Composition Scale
A DEXA scan every 3 months is the right cadence for clinical-grade body composition decisions. But 3 months is also a long time to fly blind during the most metabolically dynamic period of your GLP-1 journey — particularly in the first 90 days, when fat loss, lean mass shifts, and fluid changes happen the fastest.
This is where an at-home body composition scale becomes the essential complement to your DEXA scans — not a replacement, but the tool that fills the 90-day measurement gap between clinical reference points.
The role each tool plays
| Tool | Purpose | Frequency | What it gives you |
|---|---|---|---|
| DEXA scan | Clinical-grade reference standard | Every 3 months | The true, accurate measurement — your "source of truth" |
| At-home body composition scale | Daily/weekly trend tracking between scans | 2–4 times per week | Direction of movement — are you on the right trajectory? |
The two tools serve fundamentally different purposes and the most successful GLP-1 patients use both.
Why trending matters more than absolute precision between scans
Here is the key insight that gets missed in most body composition discussions: for trend tracking, precision matters less than consistency.
A DEXA scan gives you a number that is accurate to within 1–2% of your true body composition. An at-home bioelectrical impedance (BIA) scale typically has a wider absolute margin of error — but if you weigh yourself on the same scale, at the same time of day, in the same hydration state, every single time, the trend the scale reveals is genuinely informative even if the absolute number is not perfectly accurate.
In other words: your scale may report your body fat percentage as 24% when DEXA says 22%, but if your scale shows you dropping from 24% to 21% over 8 weeks, that 3-point downward trend is real. The relative change is reliable even when the absolute number is not.
This is the same principle that makes blood pressure cuffs useful at home — your home cuff may read slightly differently than the clinic cuff, but the daily trend on your own device tells you whether your medication is working.
What an at-home scale can tell you between DEXA scans
A modern multi-frequency body composition scale — particularly one with segmental (8-electrode) measurement that assesses each limb separately — can track:
- Total body weight (the basic but essential daily signal)
- Body fat percentage trend (is fat loss happening at the expected rate?)
- Lean body mass trend (is muscle holding, or trending down?)
- Body water shifts (which can produce misleading scale-weight changes that are not actually fat loss)
- Visceral fat estimate (less accurate than DEXA, but useful for trending)
- Segmental muscle distribution (left vs. right, upper vs. lower — useful for catching asymmetric muscle loss)
Eight-electrode scales are meaningfully more accurate than typical 2- or 4-electrode bathroom scales because they measure resistance through each limb individually rather than estimating the entire body from foot-to-foot or hand-to-hand impedance.
Why this matters specifically for GLP-1 users
GLP-1 weight loss happens in a non-linear pattern. Some weeks the scale moves 2–3 pounds. Some weeks it does not move at all. Some weeks it moves up despite continued caloric deficit because of water retention, glycogen shifts, or normal physiological fluctuation.
Without between-scan trend data, it is nearly impossible to tell:
- Whether a "stall" is real or a hydration artifact
- Whether your scale weight gain this week is fat regain or water
- Whether your protein and resistance training adjustments after Scan 2 are actually preserving muscle
- Whether you need to push for more aggressive intervention or stay the course
An at-home scale gives you that data every few days, so by the time your next DEXA scan arrives at the 3-month mark, you already have a working hypothesis about what you will find — and you have not lost 12 weeks of potential course corrections waiting for the clinical scan.
How to use an at-home scale correctly for GLP-1 trend tracking
The accuracy of any BIA-based scale depends almost entirely on measurement consistency. Follow these rules:
- Same time of day, every time. First thing in the morning, after using the bathroom, before eating or drinking, is the most reproducible window.
- Same hydration state. Significant dehydration or fluid overload will shift readings independent of any real composition change.
- Same scale, always. Different scales produce different absolute values. Pick one and stay with it.
- Same surface and same position. Bare feet, dry skin, scale on hard flooring rather than carpet.
- Look at the rolling 7-day or 14-day average, not the daily number. Daily fluctuation is dominated by water shifts. Weekly and biweekly averages reveal the true trend.
- Anchor to your DEXA scan. When you get your next DEXA scan, note the absolute numbers from your scale that same day. You now know the offset between your scale and clinical reality, which makes every subsequent at-home reading more informative.
The DEXA+ Body Fat Scale: built for between-scan tracking
For GLP-1 patients specifically, the DEXA+ Body Fat Scale was designed to integrate directly with the DEXA Scan app and the DEXASCAN.com clinical scan network — so your at-home readings and your in-clinic DEXA scans live in the same trend chart, on the same timeline, with your scan-day offsets automatically reconciled.
Features specifically valuable for GLP-1 users:
- 8-electrode segmental BIA measuring each limb individually (more accurate than typical 2- or 4-electrode scales)
- 52 body composition measurements including segmental lean mass, segmental fat distribution, visceral fat estimate, body water, and metabolic age
- Direct integration with the DEXA Scan app — your scale readings and DEXA scan results appear in the same trend graph
- Multi-user profiles — track yourself and other household members separately
- Bluetooth sync — automatic data capture, no manual logging
The scale is not a replacement for a DEXA scan. It is the between-scan dashboard that makes the 3-month DEXA cadence actually workable in real life.
Learn more about the DEXA+ Body Fat Scale →
How to Protect Muscle and Bone While on a GLP-1
The interventions that meaningfully shift body composition outcomes on GLP-1 therapy are well-established and consistent across the clinical literature:
1. Resistance training, started at the same time as the medication
Not after you have lost weight. Not after you "feel ready." At the same time. 2–4 sessions per week of progressive resistance training is the single most powerful tool for preserving lean mass during any weight loss intervention, GLP-1 included. The training does not need to be elaborate — full-body compound movements, performed consistently with progressive overload, are sufficient.
2. High protein intake
Target 1.2–1.6 grams of protein per kilogram of body weight per day during active weight loss, distributed across 3–4 meals to maximize per-meal muscle protein synthesis. This is roughly 80–120 grams of protein per day for most adults — substantially higher than the standard RDA of 0.8 g/kg, which is a maintenance floor for sedentary younger adults, not a target for adults losing 15–25% of their body weight.
The challenge for GLP-1 users specifically: appetite suppression makes hitting protein targets harder, not easier. Many patients find front-loading protein in the morning (when appetite is highest) and using high-protein liquid supplements (when solid food is unappealing) helpful.
3. Adequate weight-bearing and impact-loading exercise for bone
Resistance training supports bone density. Walking helps. Running, jumping, and plyometric work help more. Swimming and cycling — while excellent for cardiovascular health — do not significantly load bone.
4. Calcium and vitamin D adequacy
Calcium intake of 1,000–1,200 mg/day and serum 25-OH vitamin D in the 30–50 ng/mL range support bone mineralization during weight loss.
5. Adequate sleep
Sleep deprivation impairs muscle protein synthesis and increases muscle breakdown. 7+ hours per night supports the muscle-preserving effects of all the above.
6. Measurement
You cannot improve what you cannot see. The DEXA scan is the feedback loop that tells you whether your protocol is working.
Why a Whole-Body DEXA Scan Is the Right Tool for GLP-1 Tracking
Several methods can measure body composition. Only one is well-suited to GLP-1 tracking specifically:
| Method | Accuracy | Tracks lean vs. fat? | Tracks visceral fat? | Tracks bone? | Practical for serial scans? |
|---|---|---|---|---|---|
| Bathroom scale | Total weight only | No | No | No | Yes — but doesn't answer the question |
| BMI calculator | Total weight only | No | No | No | Yes — but doesn't answer the question |
| Tape measure | Circumference only | No | Crude proxy | No | Yes — but limited insight |
| Smart scale (BIA) | Modest for absolute values, useful for trending | Yes (estimated) | Limited | No | Yes — ideal for between-DEXA trend tracking |
| Bod Pod | Good | Yes | No | No | Yes |
| DEXA scan | ±1–2% margin of error | Yes — directly | Yes — directly | Yes | Yes — radiation is trivial |
| MRI | Excellent | Yes | Yes | Limited | No — too expensive |
| CT scan | Excellent | Yes | Yes | Limited | No — radiation too high for serial use |
For GLP-1 monitoring specifically, DEXA's combination of clinical-grade accuracy, low cost relative to MRI, low radiation exposure suitable for repeat scanning, and direct measurement of all four key metrics (fat, lean, visceral fat, bone) makes it the standard.[^7][^8]
Track Your GLP-1 Body Composition Journey in the DEXA Scan App
A single scan tells you where you are. A trend tells you whether your protocol is working. The free DEXA Scan app, available on iOS and Android, lets you:
- Store every DEXA scan in one secure place
- Visualize your fat mass, lean mass, ALMI, VAT, and BMD trends across your GLP-1 journey
- Compare your numbers to age- and sex-matched reference ranges
- Receive evidence-based recommendations tied to your specific results
- Book your next follow-up scan at any DEXASCAN.com network clinic
Frequently Asked Questions About DEXA Scans for GLP-1 Users
Do I really need a DEXA scan to use a GLP-1 effectively?
"Need" depends on your goals. If you only care about scale weight, no. If you care about long-term health, metabolic function, muscle preservation, bone health, and post-treatment body composition, yes — direct measurement is the only way to know what is actually happening.
How much muscle loss is normal on a GLP-1?
Published data suggest that lean mass typically accounts for roughly 25–45% of total weight loss on semaglutide and 25–35% on tirzepatide in clinical trial populations, with substantial individual variation.[^1][^4] In adults with structured resistance training and adequate protein intake, the lean mass fraction tends to be at the lower end. In sedentary adults with low protein intake, it can be substantially higher.
When should I get my first DEXA scan if I'm already on a GLP-1?
As soon as possible. While a true baseline before starting the medication is ideal, a "current state" scan now still provides actionable data and a reference for future scans. The second-best time to measure is today.
Will my insurance cover a DEXA scan for GLP-1 monitoring?
Generally, no — most whole-body DEXA body composition scans are paid out-of-pocket as a wellness service. HSA and FSA funds typically can be used. Diagnostic DEXA scans for osteoporosis screening are sometimes covered by insurance, but body composition tracking specifically usually is not.
How does the DEXA scan compare to my smart scale at home?
DEXA and an at-home scale do different jobs. DEXA is the clinical reference standard — accurate to within 1–2% of true body composition and the right tool for high-stakes decisions every 3 months. A good at-home body composition scale (particularly one with 8-electrode segmental BIA) is less accurate for absolute values but excellent for tracking trends between DEXA scans when used consistently. The most successful GLP-1 patients use both: DEXA for the source-of-truth reference points, an at-home scale for the daily and weekly direction-of-movement signals. See the dedicated section above on between-scan tracking for the full protocol.
How often should I weigh myself on an at-home body composition scale during GLP-1 therapy?
For most adults, 2–4 times per week under consistent conditions (same time of day, same hydration state) is the sweet spot. Daily weighing is fine if it does not become psychologically counterproductive — but interpret the numbers as a rolling 7-day average rather than reacting to single-day readings. Daily fluctuations are dominated by water shifts and do not reflect actual body composition changes.
What features should I look for in a body composition scale for GLP-1 tracking?
The most important features are: 8-electrode segmental measurement (significantly more accurate than 2- or 4-electrode bathroom scales), multi-frequency BIA (more reliable across hydration states), app integration (so trends are visualized over time rather than recorded in isolation), and multi-user profiles (so the data stays clean if multiple household members use the same scale). The DEXA+ Body Fat Scale was specifically designed to integrate with the DEXA Scan app so at-home readings and clinical DEXA results appear in the same trend chart.
What if my 3-month scan shows I've lost too much muscle?
The fix is straightforward: add or intensify resistance training, raise protein intake to 1.4–1.6 g/kg/day, ensure adequate sleep, and rescan in 8–12 weeks to verify the protocol is working. Working with your prescribing physician on dose timing or adjustment may also be appropriate.
Do I need to stop my GLP-1 before a DEXA scan?
No. The medication itself does not affect the scan. You should follow standard pre-scan guidance from your clinic (consistent hydration, mild fasting if recommended, no metal in the scan area).
The Bottom Line
GLP-1 medications are transformative tools for medical weight loss. But the scale alone cannot tell you whether the weight you are losing is the kind you actually want to lose. Without body composition measurement, you are flying blind through one of the most consequential health interventions of your life.
A baseline DEXA scan plus a 3-month follow-up changes that.
Find a DEXASCAN.com clinic near you and book your GLP-1 baseline scan →
Download the DEXA Scan app to track your body composition through your GLP-1 journey →
Read next:
- What Does a DEXA Scan Actually Measure? The Complete Guide
- Appendicular Lean Mass Index (ALMI): The DEXA Scan Number That Predicts How Well You'll Age
- Visceral Adipose Tissue (VAT): What It Is, Why It's the Most Dangerous Fat in Your Body
- Fat Mass Index (FMI) vs BMI: Why the Number Your Doctor Uses Is Hiding Your Real Health Risk
References
[^1]: New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Reviews in Endocrine and Metabolic Disorders. 2025. Available at: https://link.springer.com/article/10.1007/s11154-025-09967-4
[^2]: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity — DEXA substudy. ClinicalTrials.gov NCT03548935. Available at: https://clinicaltrials.gov/study/NCT03548935
[^3]: Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. 2025. Available at: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676
[^4]: Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism. 2025. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673431/
[^5]: Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping. medRxiv preprint. 2026. Available at: https://www.medrxiv.org/content/10.64898/2026.04.11.26350687v1.full
[^6]: Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Reports Medicine. 2026. Available at: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00082-0
[^7]: DEXA Scan vs Imaging Tests — Comparison Guide. Body of Discovery clinical review of DEXA accuracy. 2026. Available at: https://www.wearebod.com/blogs/journal/dexa-scan-versus-other-imaging-tests-a-comprehensive-comparison
[^8]: Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss. Mass General Brigham Advances in Motion. 2025. Available at: https://advances.massgeneral.org/endocrinology/article.aspx?id=1601
Medical disclaimer: This article is for educational purposes and does not constitute medical advice. Decisions about GLP-1 therapy, dose adjustments, and discontinuation should be made in partnership with the prescribing physician. DEXASCAN.com clinics provide body composition measurement; clinical interpretation should be conducted with your healthcare provider.
©All rights reserved. DEXASCAN.com — the national network for whole-body DEXA scanning.